Clinical trialPhase 1 / Phase 2Recruiting
SL-28 for Advanced Solid Tumours
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 14 August 2026
- Expected end
- 1 March 2027
- Enrollment
- 60 participants
- Sites
- 3
- Primary outcomes
- Number of participants with treatment-emergent adverse events; To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion.; Change from baseline in ECG QT interval; Change from baseline in vital signs; Change from baseline in vital signs
- Sponsor
- Industry
- Results posted
- No
- Last update
- 15 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try